#1 Clinical Trials Search in Europe

Nipocalimab

Nipocalimab is an investigational drug currently being studied in clinical trials for several autoimmune diseases and conditions. This monoclonal antibody works by targeting a receptor involved in regulating antibody levels in the body. Ongoing trials are evaluating nipocalimab’s safety and effectiveness for conditions like myasthenia gravis, rheumatoid arthritis, and certain pregnancy-related disorders. Early results suggest it may help reduce disease activity in some autoimmune conditions by lowering harmful antibody levels.

Table of Contents

What is Nipocalimab?

Nipocalimab is a new medication being developed to treat various autoimmune disorders. It is also known by other names such as JNJ-80202135 and M281[1][2]. This drug is classified as a monoclonal antibody, which means it’s a type of protein designed to target specific cells or proteins in the body[3].

How Does Nipocalimab Work?

Nipocalimab works in a unique way compared to other medications. It targets a specific receptor in the body called the neonatal Fc receptor (FcRn). By blocking this receptor, nipocalimab can reduce the levels of certain antibodies in the blood that are responsible for causing autoimmune diseases[3].

In simpler terms, think of nipocalimab as a shield that blocks harmful antibodies from attacking your body. By lowering these antibodies, it can help reduce inflammation and other symptoms associated with autoimmune disorders.

Conditions Treated with Nipocalimab

Nipocalimab is being studied for several autoimmune conditions, including:

  • Generalized Myasthenia Gravis (gMG): A condition that causes muscle weakness and fatigue[1][4]
  • Warm Autoimmune Hemolytic Anemia (wAIHA): A disorder where the immune system destroys red blood cells[5]
  • Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): A condition affecting unborn babies and newborns, causing low platelet counts[6]
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A neurological disorder affecting the peripheral nerves[7]
  • Rheumatoid Arthritis (RA): An inflammatory condition affecting the joints[3]
  • Idiopathic Inflammatory Myopathies (IIM): A group of conditions causing muscle inflammation[8]
  • Hemolytic Disease of the Fetus and Newborn (HDFN): A condition where a pregnant woman’s immune system attacks her unborn baby’s red blood cells[9]

Clinical Trials and Research

Nipocalimab is currently being studied in various clinical trials to determine its effectiveness and safety. These trials are testing the drug in different patient populations and for different conditions. Some key points about the ongoing research include:

  • Studies are being conducted in adults and children with generalized myasthenia gravis[1][4]
  • Researchers are investigating its use in pregnant women to prevent conditions like FNAIT and HDFN[6][9]
  • The drug is being tested against placebo (a substance with no active ingredients) to determine its true effectiveness[3][8]
  • Some trials are looking at long-term safety and efficacy, following patients for up to 4 years[4]

How is Nipocalimab Administered?

Nipocalimab is typically given as an intravenous (IV) infusion, which means it’s delivered directly into the bloodstream through a vein[1][2]. The frequency of administration can vary depending on the condition being treated and the specific clinical trial protocol. Some studies are testing different dosing schedules, such as:

  • Every 2 weeks (q2w)[4]
  • Every 4 weeks (q4w)[5]
  • Weekly administration during pregnancy[9]

Some research is also exploring the possibility of subcutaneous (under the skin) injections of nipocalimab, which could potentially allow for easier administration in the future[10].

Potential Side Effects and Safety Considerations

As with any medication, nipocalimab may cause side effects. The ongoing clinical trials are carefully monitoring patients for any adverse events. Some potential side effects and safety considerations include:

  • Infections: Since nipocalimab affects the immune system, there’s a potential increased risk of infections[1]
  • Infusion reactions: Some patients may experience reactions during or after the IV infusion[4]
  • Changes in laboratory values: Researchers are monitoring for changes in blood tests, including immunoglobulin levels[1][2]
  • Pregnancy considerations: Special attention is being given to the safety of nipocalimab in pregnant women and their babies[9]

It’s important to note that the full safety profile of nipocalimab is still being established through ongoing clinical trials. Patients considering participation in a clinical trial should discuss potential risks and benefits with their healthcare provider.

Aspect Details
Drug Name Nipocalimab (also known as JNJ-80202135, M281)
Drug Type Fully human aglycosylated IgG1 monoclonal antibody
Mechanism of Action Selectively binds, saturates, and blocks the IgG binding site on the neonatal Fc receptor (FcRn)
Conditions Studied Generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), rheumatoid arthritis, fetal and neonatal alloimmune thrombocytopenia (FNAIT), hemolytic disease of the fetus and newborn (HDFN)
Administration Primarily intravenous (IV) infusion; some studies on subcutaneous injection
Dosing Frequency Typically every 2 or 4 weeks, depending on the study
Primary Outcomes Changes in disease activity scores, antibody levels, safety assessments
Safety Monitoring Adverse events, serious adverse events, laboratory abnormalities, vital signs, ECG changes
Special Interest Infections, injection site reactions, changes in albumin levels
Development Stage Phase 1, 2, and 3 clinical trials ongoing

FAQ

  • What is nipocalimab? Nipocalimab is an investigational monoclonal antibody designed to selectively bind to and block the neonatal Fc receptor (FcRn). This mechanism is intended to reduce levels of disease-causing antibodies in autoimmune conditions.
  • What conditions is nipocalimab being studied for? Clinical trials are evaluating nipocalimab for several autoimmune conditions, including generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy (CIDP), rheumatoid arthritis, and pregnancy-related disorders like fetal and neonatal alloimmune thrombocytopenia (FNAIT) and hemolytic disease of the fetus and newborn (HDFN).
  • How is nipocalimab administered? In most trials, nipocalimab is administered as an intravenous (IV) infusion, typically every 2 or 4 weeks. Some studies are also evaluating subcutaneous injection.
  • What are the main outcomes being measured in nipocalimab trials? Key outcomes include changes in disease activity scores, antibody levels, quality of life measures, and safety assessments like adverse events. For pregnancy-related conditions, fetal/neonatal outcomes are also evaluated.
  • Are there any known side effects of nipocalimab? While full safety data is still being collected, trials are monitoring for potential side effects like infections, injection site reactions, and changes in albumin levels. As with any investigational drug, the full safety profile is still being established through ongoing clinical studies.

Ongoing Clinical Trials on Nipocalimab

  • Study on Nipocalimab for Adults with Warm Autoimmune Hemolytic Anemia

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Greece Hungary Italy +3

  • Study on Nipocalimab and Certolizumab for Patients with Active Rheumatoid Arthritis After Advanced Therapy

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Hungary Poland

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Monoclonal antibodies are used to treat some types of cancer and other diseases.
  • Neonatal Fc receptor (FcRn): A protein found in various cells that helps regulate the levels of antibodies (immunoglobulins) in the body by protecting them from breakdown.
  • Myasthenia gravis: A chronic autoimmune disorder that causes muscle weakness and fatigue, often affecting the eyes and face, throat, and limbs.
  • Chronic inflammatory demyelinating polyneuropathy (CIDP): A rare neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms due to inflammation of peripheral nerves.
  • Rheumatoid arthritis: A chronic inflammatory disorder affecting many joints, including those in the hands and feet, causing pain, swelling, and stiffness.
  • Fetal and neonatal alloimmune thrombocytopenia (FNAIT): A blood disorder where a pregnant woman's immune system attacks the platelets of her developing baby, potentially causing severe bleeding.
  • Hemolytic disease of the fetus and newborn (HDFN): A blood disorder that occurs when there is an incompatibility between the blood types of a mother and her unborn child, leading to the destruction of the baby's red blood cells.
  • Intravenous (IV) infusion: A method of delivering medications or fluids directly into a vein using a needle or catheter.
  • Subcutaneous injection: An injection given into the fatty tissue just beneath the skin.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body and the mechanisms of drug action.
  • Anti-drug antibodies (ADAs): Antibodies produced by the immune system against a therapeutic drug, which can potentially reduce its effectiveness or cause adverse reactions.
  • Immunoglobulin G (IgG): The most common type of antibody in blood and other body fluids, playing an important role in the immune response against pathogens.

References

  1. https://clinicaltrials.eu/trial/study-on-nipocalimab-for-children-aged-2-17-with-generalized-myasthenia-gravis/
  2. https://clinicaltrials.gov/study/NCT05151692
  3. https://clinicaltrials.gov/study/NCT04991753
  4. https://clinicaltrials.eu/trial/study-on-nipocalimab-for-adults-with-generalized-myasthenia-gravis/
  5. https://clinicaltrials.gov/study/NCT05221619
  6. https://clinicaltrials.gov/study/NCT06449651
  7. https://clinicaltrials.gov/study/NCT05327114
  8. https://clinicaltrials.gov/study/NCT05379634
  9. https://clinicaltrials.gov/study/NCT05912517
  10. https://clinicaltrials.gov/study/NCT04848558